Bedrijfsoverzicht
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical entity dedicated to creating resveratrol platform products designed for the treatment of neuroinflammation. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment centered on advancing scientific knowledge and developing novel therapeutics for medical conditions. According to the available data, the company currently employs five individuals and holds a market capitalization of $14.47 million, while reporting a trailing twelve-month revenue of $21,796. These valuation and revenue figures indicate that Jupiter Neurosciences operates at a very early stage of development, typical for biotechnology firms that are prioritizing product trials over immediate profitability or significant revenue generation. The extremely low revenue relative to the market cap suggests that the company's primary value driver is the potential future success of its pipeline assets rather than current cash flow from sales.
Financiële gezondheid
The financial statements for Jupiter Neurosciences, Inc. reveal a revenue of $21,796 over the trailing twelve months, coupled with a net income of $-8,644,897 and no reported EBITDA. The substantial gap between the minimal revenue and the massive negative net income highlights an aggressive cost structure characterized by high research and development expenses that far outweigh current sales income. The company generates a free cash flow of $-2,314,987, which signifies a significant cash outflow required to fund ongoing operations and development efforts before any revenue can offset these costs. Margin analysis shows a gross margin of 0.0%, an operating margin of -12886.7%, and a profit margin of 0.0%, indicating that the company has not yet achieved commercial viability or cost efficiency at its current scale. Regarding liquidity, the company holds $3.79 million in cash against $5.32 million in debt, resulting in a debt-to-equity ratio that is listed as N/A due to the equity structure. The current ratio stands at 0.65, which indicates that the company possesses less liquid assets than short-term liabilities, suggesting potential liquidity constraints in the near term. Return on Equity is reported at -738.8% and Return on Assets at -94.6%, metrics that reveal that management is currently burning significant capital to generate value, reflecting the early-stage nature of the business where losses are expected to continue until product approval and commercialization occur.
Waarderingsbeoordeling
Valuation metrics for Jupiter Neurosciences, Inc. present a complex picture with a trailing P/E ratio listed as N/A due to the lack of net income, while the forward P/E is calculated at 6.65. The discrepancy between the absent trailing P/E and the specific forward P/E implies that analysts or the market are projecting a future path toward profitability that is not reflected in the current earnings history. The price-to-book ratio is exceptionally high at 199.40, indicating a substantial market premium over the company's book value, which is common for biotech firms where intangible assets and pipeline potential exceed recorded assets. Alternative valuation multiples such as the price-to-sales ratio of 663.84 and an EV/EBITDA of N/A further suggest that traditional valuation methods are less applicable, with the price-to-sales figure reflecting the market's willingness to pay a high multiple for future sales potential. The stock has traded between a 52-week low of $0.31 and a 52-week high of $3.33, placing the current trading position somewhere within this wide historical range. The beta value is listed as N/A, meaning that historical volatility data relative to the broader market is unavailable or not reported for this specific ticker in the current dataset.
Growth & Income
Growth metrics for Jupiter Neurosciences, Inc. are currently unavailable, with revenue growth year-over-year and earnings growth year-over-year both listed as N/A due to the company's early-stage financial history. The absence of comparable prior periods or sufficient data prevents a calculation of growth rates, though the negative earnings growth implied by the losses suggests the company is investing heavily rather than scaling profitable operations. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash is being reinvested directly into research, development, and clinical trials rather than being distributed to shareholders. This reinvestment strategy is typical for biotechnology companies at this stage, where capital allocation focuses entirely on advancing the resveratrol platform and achieving regulatory milestones for JNS101 in Phase II trials for Friedreich's Ataxia. The overall growth and income profile is characterized by a complete reliance on future potential rather than current financial performance, with zero dividends and significant cash burn defining the current investment characteristics of the asset.